Activez les alertes d’offres d’emploi par e-mail !
Générez un CV personnalisé en quelques minutes
Décrochez un entretien et gagnez plus. En savoir plus
Une position de doctorant est ouverte dans le cadre du projet Nanologic, visant à développer des CAR-T multis spécifiques pour la thérapie du glioblastome. Les candidats doivent avoir une formation solide en immuno-oncologie et en biologie cellulaire, avec des compétences en ingénierie des protéines. Le poste commence le 1er octobre 2025 avec une durée temporaire. Les candidatures doivent être envoyées par email à l’adresse spécifiée.
Organisation/Company Centre de Recherche en Cancérologie de Marseille Research Field Biological sciences » Biology Researcher Profile First Stage Researcher (R1) Positions PhD Positions Country France Application Deadline 20 Jul 2025 - 00:00 (Europe/Paris) Type of Contract Temporary Job Status Full-time Offer Starting Date 1 Oct 2025 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
CONTEXT
Chimeric antigen receptor (CAR) T-cell therapies have demonstrated considerable efficacy in treating hematological malignancies. However, their therapeutic potential is hindered by several challenges, including difficulty identifying tumor-specific antigens and loss of target antigen expression on malignant cells, which is a common mechanism of tumor immune evasion.
Innovative approaches, such as conditionally activated CAR T cells based on Boolean logic (e.g., OR or AND gates), offer a promising solution to these limitations. These approaches make it possible to activate CAR T cells based on the presence of one and/or two tumor markers, thereby increasing their efficacy and safety. However, these technologies are complex to implement and transfer to the clinic because they are generally based on the transduction of multiple engineered receptors.
MISSIONS
The Nanologic project aims to develop “all-in-one” multispecific CARs by concatenating nanobodies (Nb), specific single-domain molecules, to confer conditional activation to CAR-T cells with a single receptor. The two main missions of the PhD applicant wiil be:
-Create multispecific CARs integrating Nb for conditionnal OR-gate activation and AND-gate activation
-Produce and evaluate the activity of CAR-T cells expressing these receptors in vitro.
-Transfer NanoCAR technology to target glioblastoma (GBM) and evaluate CAR T cells in preclinical models
-Production and functional evaluation of CAR-T cells expressing these receptors on GBM preclinical model
E-mail remi.lasserre@inserm.fr
Research Field Biological sciences » Biology Education Level Master Degree or equivalent
Skills/Qualifications
• Strong background in immuno-oncology and cell biology
• Advanced skills in protein engineering, primary cell culture, cytometry, and microscopy
• Fluency in scientific English (written and oral) required, French is an asset
• Ability to produce recombinant proteins in both eukaryotic and prokaryotic systems.
• Ability to purify immune primary cells
• Scientific rigor and autonomy
• Team spirit, ability to collaborate with different teams.
• Intellectual curiosity and creative problem-solving skills
• Effective organization and time management for complex projects
Languages ENGLISH Level Good
Languages FRENCH Level Basic
Research Field Biological sciences » Biology
Selection process
We are seeking highly motivated candidates to join our team.
To apply, please submit your application via email. Your application must include the following:
Shortlisted candidates will be contacted for an interview as part of the final selection process.